Article
Virology
Shou-Wu Lee, Li-Shu Chen, Sheng-Shun Yang, Yi-Hsiang Huang, Teng-Yu Lee
Summary: In patients with BCLC stage B/C HCC, DAA therapy can achieve a high SVR rate, except for those with PD to prior HCC treatments. SVR is related to improvements in OS, therefore, DAA therapy should be encouraged for patients diagnosed without a short life expectancy.
Article
Medicine, General & Internal
Yun-Cheng Hsieh, Kuei-Chuan Lee, Chien-Wei Su, Ken-Hsin Lan, Teh-Ia Huo, Yuan-Jen Wang, Hui-Chun Huang, Han-Chieh Lin, Chi-Jen Chu, Yi-Hsiang Huang, Ming-Chih Hou
Summary: The study found that persistent elevation of aminotransferase levels is not uncommon in patients with advanced fibrosis after DAA treatment, and it is associated with impaired baseline liver function and steatosis. Long-term follow-up is needed to assess the impact of liver inflammation on disease progression.
JOURNAL OF THE CHINESE MEDICAL ASSOCIATION
(2021)
Article
Medicine, General & Internal
Akio Miyasaka, Yuichi Yoshida, Akiko Suzuki, Kei Sawara, Yasuhiro Takikawa
Summary: This study investigated the long-term incidence of HCC after achieving SVR with DAA treatment for HCV, finding that Fib-4 index and previous HCC history were independent predictors for the development of HCC post-treatment. A novel scoring system based on these factors was established to identify patients at higher risk for HCC occurrence. Patients with these risk factors should be closely monitored.
INTERNATIONAL JOURNAL OF GENERAL MEDICINE
(2021)
Article
Oncology
Taisuke Imamura, Yukiyasu Okamura, Keiichi Ohshima, Katsuhiko Uesaka, Teiichi Sugiura, Takaaki Ito, Yusuke Yamamoto, Ryo Ashida, Katsuhisa Ohgi, Shimpei Otsuka, Sumiko Ohnami, Takeshi Nagashima, Keiichi Hatakeyama, Yuko Kakuda, Takashi Sugino, Kenichi Urakami, Yasuto Akiyama, Ken Yamaguchi
Summary: This study compared the genomic characteristics of hepatocellular carcinoma (HCC) in patients with hepatitis C virus infection who achieved sustained virological response (SVR) or not after surgery using gene expression profiling and whole-exome sequencing. The study found significant differences in mutation rates of several driver genes between HCCs of SVR patients and non-SVR patients, as well as between HCCs of SVR patients treated with direct-acting antivirals (DAA) and interferon (IFN).
Article
Gastroenterology & Hepatology
Maria Sanchez-Azofra, Inmaculada Fernandez, Maria L. Garcia-Buey, Lourdes Dominguez-Dominguez, Conrado M. Fernandez-Rodriguez, Antonio Mancebo, Lucia Bonet, Pablo Ryan, Francisco Gea, Antonio Diaz-Sanchez, Marian Garcia-Mayor, Luz Martin-Carbonero, Pilar Castillo, Maria L. Manzano, Leticia Gonzalez-Moreno, Federico Pulido, Maria L. Gutierrez, Jose M. Moreno, Irene M. Garcia-Amengual, Guillermo Cuevas, Antonio Guerrero, Miguel Rivero-Fernandez, Maria E. Portales, Maria L. Montes, Antonio Olveira
Summary: Among patients with chronic hepatitis C and stage 3 fibrosis, the risk of developing primary liver tumors after sustained virological response is low, except for males older than 55 years, who have a significantly higher risk.
LIVER INTERNATIONAL
(2021)
Article
Gastroenterology & Hepatology
Shogo Tanaka, Hiroji Shinkawa, Akihiro Tamori, Shigekazu Takemura, Sawako Uchida-Kobayashi, Ryosuke Amano, Kenjiro Kimura, Go Ohira, Kohei Nishio, Jun Tauchi, Masahiko Kinoshita, Norifumi Kawada, Shoji Kubo
Summary: A study examined the effects of direct-acting antiviral (DAA)-induced sustained virological response (SVR) in patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC) after liver resection. While DAA-induced SVR itself may not suppress postoperative recurrence, the study found that DAA treatment improved liver function and prolonged postoperative survival in patients.
HEPATOLOGY RESEARCH
(2021)
Review
Medicine, General & Internal
Tanawat Jongraksak, Alan Chuncharunee, Pongphob Intaraprasong, Amarit Tansawet, Ammarin Thakkinstian, Abhasnee Sobhonslidsuk
Summary: DAA treatment can improve overall survival and MELD score in patients with HCV decompensated cirrhosis, with a marginal effect on HCC development.
FRONTIERS IN MEDICINE
(2023)
Article
Medicine, General & Internal
Mariana Sandoval Lourenco, Patricia Momoyo Y. Zitelli, Marlone Cunha-Silva, Arthur Ivan N. Oliveira, Roque Gabriel Rezende de Lima, Souza Evandro de Oliveira, Claudia P. Oliveira, Tiago Seva-Pereira, Flair J. Carrilho, Mario G. Pessoa, Daniel F. Mazo
Summary: In patients with decompensated HCV cirrhosis, a high SVR rate was achieved with interferon-free therapy. Early improvement in liver function was observed after successful HCV eradication. Nonetheless, long-term follow-up of these patients post-SVR is strongly recommended.
Article
Gastroenterology & Hepatology
Shereen Abdel Alem, Rasha Eletreby, Zeinab Abdellatif, Ahmed Ramadan, Ahmed Nagy, Mohamed AbdAllah, Aisha Elsharkawy, Rabab Fouad, Gamal Esmat, Omnia Tantawi
Summary: This 3-year follow-up study demonstrates the durability of SVR, improvement of liver function parameters and ALBI score and grade in patients with an advanced stage of fibrosis after successful treatment with DAAs. Patients with advanced fibrosis and cirrhosis showed a more pronounced improvement in liver stiffness during follow-up.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
(2021)
Article
Gastroenterology & Hepatology
Heiner Wedemeyer, Peter Erren, Uwe Naumann, Ansgar Rieke, Albrecht Stoehr, Tim Zimmermann, Kristina Lohmann, Bettina Koenig, Stefan Mauss
Summary: This study evaluated the real-world safety and effectiveness of Glecaprevir/pibrentasvir treatment in patients with cirrhosis from the German Hepatitis C-Registry. The results showed that Glecaprevir/pibrentasvir was well-tolerated and highly effective in patients with chronic hepatitis C and cirrhosis in real-world practice.
LIVER INTERNATIONAL
(2021)
Review
Oncology
Roberta D'Ambrosio, Elisabetta Degasperi, Pietro Lampertico
Summary: Chronic infection with hepatitis C virus (HCV) can lead to hepatocellular carcinoma (HCC), especially in patients with cirrhosis. The risk of HCC development is more strongly influenced by pre-treatment fibrosis stage and prior HCC history than the type of antiviral therapy. Rates of de-novo HCC are higher in patients with cirrhosis, while rates of recurrent HCC are more common in cirrhotics.
JOURNAL OF HEPATOCELLULAR CARCINOMA
(2021)
Review
Biochemistry & Molecular Biology
Francesco Paolo Russo, Alberto Zanetto, Elisa Pinto, Sara Battistella, Barbara Penzo, Patrizia Burra, Fabio Farinati
Summary: Hepatocellular carcinoma (HCC) is a major cause of cancer-related death, with chronic viral hepatitis being a significant contributing factor. The pathophysiology of viral-related HCC involves liver inflammation, oxidative stress, and deregulation of cell signaling pathways. Regular ultrasound surveillance is recommended for patients with cirrhosis and high-risk individuals with chronic HBV infection. Antiviral therapy reduces the risks of HCC development and recurrence. Various scoring systems have been developed to predict the risk of HCC development in patients with chronic hepatitis B.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Gastroenterology & Hepatology
Kazuki Maesaka, Ryotaro Sakamori, Ryoko Yamada, Yuki Tahata, Masahide Oshita, Hideki Hagiwara, Mitsuru Sakakibara, Shinji Tamura, Naoki Hiramatsu, Masami Inada, Sadaharu Iio, Toshifumi Ito, Takayuki Yakushijin, Yoshinori Doi, Takahiro Kodama, Hayato Hikita, Tomohide Tatsumi, Tetsuo Takehara
Summary: The study aimed to investigate the clinical course in HCV-positive patients with decompensated liver cirrhosis after DAAs treatment. Approximately one-fourth of the patients received DAA treatment, but more than 40% lost the opportunity for it. Overall survival was significantly shorter and the HCC occurrence and hospitalization rates were higher in C-P C patients than in C-P B patients.
HEPATOLOGY RESEARCH
(2021)
Article
Gastroenterology & Hepatology
Yuki Tahata, Ryotaro Sakamori, Kazuki Maesaka, Akira Doi, Ryoko Yamada, Takahiro Kodama, Hayato Hikita, Masanori Miyazaki, Yasutoshi Nozaki, Akira Kaneko, Masahide Oshita, Satoshi Tanaka, Kazuho Imanaka, Naoki Hiramatsu, Naoki Morishita, Kazuyoshi Ohkawa, Takayuki Yakushijin, Mitsuru Sakakibara, Sadaharu Iio, Yoshinori Doi, Tomohide Tatsumi, Tetsuo Takehara
Summary: The aim of this study was to determine the impact of direct-acting antiviral therapy on the long-term prognosis of decompensated cirrhotic patients. Results showed that the cumulative incidence rates of decompensated events and overall survival rates were significantly better in the group receiving direct-acting antiviral therapy compared to the control group. However, there was no significant difference in the incidence of hepatocellular carcinoma between the two groups.
HEPATOLOGY RESEARCH
(2023)
Article
Gastroenterology & Hepatology
Toshifumi Tada, Takashi Nishimura, Tomomitsu Matono, Masahiro Yoshida, Minako Yuri, Aoi Fujiwara, Yukihisa Yuri, Tomoyuki Takashima, Nobuhiro Aizawa, Naoto Ikeda, Hirayuki Enomoto, Takashi Kumada, Hiroko Iijima
Summary: This study investigated risk factors for hepatocellular carcinoma (HCC) in patients with chronic hepatitis C virus who received direct-acting antiviral therapy and achieved sustained virological response. Results showed that a high TE value was significantly associated with HCC development, while CAP was not.
HEPATOLOGY RESEARCH
(2021)
Review
Gastroenterology & Hepatology
Daniel Q. Huang, Philippe Mathurin, Helena Cortez-Pinto, Rohit Loomba
Summary: Global alcohol consumption has increased, leading to a rise in the incidence of alcohol-associated cirrhosis and hepatocellular carcinoma. Heavy alcohol consumption is a major cause of morbidity and mortality. Measures are needed to reduce the burden of alcohol-related liver diseases.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Lena Allweiss, Barbara Testoni, Mei Yu, Julie Lucifora, Chunkyu Ko, Bingqian Qu, Marc Luetgehetmann, Haitao Guo, Stephan Urban, Simon P. Fletcher, Ulrike Protzer, Massimo Levrero, Fabien Zoulim, Maura Dandri
Summary: A major goal of hepatitis B virus (HBV) treatments is to reduce or inactivate intrahepatic viral covalently closed circular DNA (cccDNA). There are different methods for cccDNA quantification, such as Southern blot (SB) and quantitative PCR (qPCR). This study compared various protocols for cccDNA isolation and qPCR quantification in liver tissues and cell cultures, aiming to develop evidence-based guidance for best practices.
Editorial Material
Gastroenterology & Hepatology
Fabien Zoulim, Barbara Testoni
JOURNAL OF HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Julie Lucifora, Dulce Alfaiate, Caroline Pons, Maud Michelet, Ricardo Ramirez, Floriane Fusil, Fouzia Amirache, Axel Rossi, Anne-Flore Legrand, Emilie Charles, Serena Vegna, Rayan Farhat, Michel Rivoire, Guillaume Passot, Nicolas Gadot, Barbara Testoni, Charlotte Bach, Thomas F. Baumert, Anastasia Hyrina, Rudolf K. Beran, Fabien Zoulim, Andre Boonstra, Hildegard Buening, Eloi R. Verrier, Francois-Loic Cosset, Simon P. Fletcher, Anna Salvetti, David Durantel
Summary: This study elucidates the molecular mechanisms underlying how HDV interferes with HBV in patients with chronic coinfection. The researchers found that HDV induces the expression of interferon-stimulated genes (ISGs), and these genes are upregulated in HDV/HBV-coinfected patients. Inhibiting the hepatocyte's response to interferon partially restores the levels of HBV.
JOURNAL OF HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Pierre Nahon, Jessica Bamba-Funck, Richard Layese, Eric Trepo, Jessica Zucman-Rossi, Carole Cagnot, Nathalie Ganne-Carrie, Cendrine Chaffaut, Erwan Guyot, Marianne Ziol, Angela Sutton, Etienne Audureau
Summary: This study evaluated the ability of single nucleotide polymorphisms (SNPs) to refine hepatocellular carcinoma (HCC) risk stratification. Several genetic variants affecting lipid turnover and the Wnt-I3-β-catenin pathway were found to be associated with HCC occurrence. Incorporating these genetic variants into clinical scores improved their predictive performance for HCC.
JOURNAL OF HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Laurent Lam, Helene Fontaine, Nathanael Lapidus, Jonathan Bellet, Clovis Lusivika-Nzinga, Jerome Nicol, Celine Dorival, Carole Cagnot, Gilles Hejblum, Stanislas Pol, Marc Bourliere, Fabrice Carrat, NRS AFEF HEPATHER Std Grp
Summary: This study evaluated the validity of algorithms for identifying patients with chronic HBV or HCV infection. The results showed that multi-criteria algorithms perform well in identifying these patients and can be used to estimate the public health burden associated with hepatitis B and C in France.
JOURNAL OF VIRAL HEPATITIS
(2023)
Review
Gastroenterology & Hepatology
Seng Gee Lim, Thomas F. Baumert, Carolina Boni, Ed Gane, Massimo Levrero, Anna S. Lok, Mala K. Maini, Norah A. Terrault, Fabien Zoulim
Summary: Functional cure of chronic hepatitis B (CHB), achieved through hepatitis B surface antigen (HBsAg) loss after 24 weeks off therapy, is the goal of current treatment. However, the rarity of achieving this cure with current therapy highlights the need for novel approaches. The three categories of treatment include reducing viral replication, reducing antigen load, and immunotherapies. Combination therapy of nucleos(t)ide analogues and immunotherapy shows promise in reducing HBsAg levels and inducing HBsAg loss in some patients, particularly those with low baseline HBsAg levels. Monitoring during therapy using viral and immunological biomarkers is important to predict HBsAg loss and understand its mechanisms.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY
(2023)
Article
Public, Environmental & Occupational Health
Laurent Lam, Helene Fontaine, Nathanael Lapidus, Celine Dorival, Jonathan Bellet, Dominique Larrey, Pierre Nahon, Alpha Diallo, Carole Cagnot, Clovis Lusivika-Nzinga, Francois Teoule, Gilles Hejblum, Marc Bourliere, Stanislas Pol, Fabrice Carrat
Summary: This study examined the impact of direct-acting antivirals (DAAs) on cardiovascular events and extrahepatic cancers in patients with chronic hepatitis C (CHC). The results showed that DAAs reduced the risk of peripheral arterial disease (PAD) and had a beneficial effect on overall cardiovascular outcomes in patients with advanced fibrosis. However, there was an increased risk of arrhythmias and conduction disorders (ACD) after the first year of DAA therapy. There was no association between DAA use and extrahepatic cancer risk. Therefore, long-term cardiac monitoring is necessary after DAA therapy.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
(2023)
Article
Gastroenterology & Hepatology
Sarah Duponchel, Lea Monnier, Jennifer Molle, Nadia Bendridi, Muhammad Rizwan Alam, Ahmed Gaballah, Boyan Grigorov, Alexander Ivanov, Marcel Schmiel, Margarete Odenthal, Michel Ovize, Jennifer Rieusset, Fabien Zoulim, Birke Bartosch
Summary: Chronic HCV infection causes cellular stress, fibrosis, and predisposes to hepatocarcinogenesis. Mitochondria play key roles in orchestrating stress responses. The study revealed that HCV proteins associate with mitochondria and alter the composition of mitochondrial subdomains, which are crucial for efficient viral replication.
Article
Gastroenterology & Hepatology
Milan J. Sonneveld, Shao-Ming Chiu, Jun Yong Park, Sylvia M. Brakenhoff, Apichat Kaewdech, Wai-Kay Seto, Yasuhito Tanaka, Ivana Carey, Margarita Papatheodoridi, Piero Colombatto, Florian van Boemmel, Thomas Berg, Fabien Zoulim, Sang Hoon Ahn, George N. Dalekos, Nicole S. Erler, Maurizia Brunetto, Heiner Wedemeyer, Markus Cornberg, Man-Fung Yuen, Kosh Agarwal, Andre Boonstra, Maria Buti, Teerha Piratvisuth, George Papatheodoridis, Chien-Hung Chen, Benjamin Maasoumy, Create Study Grp
Summary: This study investigated the association between pretreatment HBV DNA levels and outcomes after therapy cessation in patients with chronic hepatitis B. It was found that lower pretreatment HBV DNA levels were associated with a lower risk of clinical relapse and a higher chance of HBsAg loss after cessation of NUC therapy. These findings can help select patients for treatment withdrawal and guide intensity of off-treatment monitoring.
Article
Gastroenterology & Hepatology
Francois Vileret, Fanny Lebosse, Sylvie Radenne, Didier Samuel, Bruno Roche, Jean-Yves Mabrut, Vincent Leroy, Georges-Philippe Pageaux, Rodolphe Anty, Sylvie Thevenon, Sinafa Si Ahmed, Aaron Hamilton, Marintha Heil, Caroline Scholtes, Massimo Levrero, Barbara Testoni, Fabien Zoulim, ECOGREFFE Study Grp
Summary: This study found that viral recurrence can occur rapidly after liver transplantation, despite prophylaxis with nucleos(t)ide analogues (NUCs) and hepatitis B immunoglobulin (HBIG). The majority of patients had at least one HBV marker detected in either serum or the liver 12 months after transplantation. Optimal patient compliance to antiviral prophylaxis is crucial to prevent viral rebound.
Article
Pharmacology & Pharmacy
Thierry Verbinnen, Willem Talloen, Harry L. A. Janssen, Fabien Zoulim, Umesh Shukla, Joris J. Vandenbossche, Michael Biermer, Sandra De Meyer, Oliver Lenz
Summary: The study investigates the viral mutations in patients with hepatitis B virus infection treated with JNJ-56136379. The results demonstrate that viral breakthroughs and emergence of drug-resistant variants occurred during JNJ-56136379 monotherapy. However, the addition of nucleos(t)ide analogue treatment effectively controlled the viral mutations. This suggests that JNJ-56136379 monotherapy may not be suitable for patients with hepatitis B.
ANTIVIRAL RESEARCH
(2023)
Article
Medicine, General & Internal
Simon Galmiche, Tiffany Charmet, Arthur Rakover, Laura Schaeffer, Olivia Cheny, Cassandre von Platen, Faiza Omar, Christophe David, Alexandra Mailles, Fabrice Carrat, Arnaud Fontanet
Summary: This study aimed to understand the contribution of children to the risk of SARS-CoV-2 infection in household members. The study found that living with children, especially very young ones, was associated with an increased risk of SARS-CoV-2 infection, particularly during the Delta and Omicron BA.1 waves. These findings can help guide policies targeting children and immunocompromised members of households.
Article
Gastroenterology & Hepatology
Xiaoqi Yu, Qiming Gong, Demin Yu, Yongyan Chen, Ying Jing, Fabien Zoulim, Xinxin Zhang
Summary: Active HBV integration events are present in the liver tissue of patients with chronic HBV infection, including those with HBsAg loss. Antiviral treatment can decrease the number and extent of transcriptionally active viral integrations, suggesting that early treatment intervention may further reduce the risk of HBV infection.
Article
Respiratory System
Thomas El Jammal, Francois Dhelft, Pierre Pradat, Francois Bailly, Fabien Zoulim, Arnaud Hot, Maxime Fauter, Ayoub Drissi-Bakhkhat, Isabelle Durieu, Jean-Christophe Lega, Yvan Jamilloux, Pascal Seve
Summary: This study suggests that lymphopenia and sACE may be valuable biomarkers for sarcoidosis diagnosis in patients with granulomatous hepatitis when combined, especially in younger patients.
SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES
(2023)